GMAB | Genmab A/S Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	21.31 - 21.85
52 Week Range	19.85 - 31.88
Beta	0.88
Implied Volatility	45.54%
IV Rank	65.90%
Day's Volume	890,304
Average Volume	1,254,881
Shares Outstanding	635,239,910
Market Cap	13,848,230,038
Sector	Healthcare
Industry	Biotechnology
IPO Date	2009-06-01

Valuation
Profitability
Growth
Health
P/E Ratio	21.80
Forward P/E Ratio	28.69
EPS	1.00
1YR Price Target	40.50
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	2,635
Country	Denmark
Website	GMAB

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab is also the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), and Tivdak (partnered wth Seagen) for cervical cancer. Genmab has several pipeline candidates targeting other oncologic indications.

GMAB's peers: ASND, APLS, BGNE, AKRO, BPMC, DAWN, MRTX, AMLX, TERN, LEGN, PCVX, TVTX, ALEC, CYTK, EWTX

*Chart delayed

Analyzing fundamentals for GMAB we got that it has strong fundamentals where Valuation is considered to be undervalued, Profitability is very wealthy, Growth is exceptionally good and Health is strong. For more detailed analysis please see GMAB Fundamentals page.

Watching at GMAB technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, but short-term trend is bullish. More technicals details can be found on GMAB Technicals page.